Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

WDHD1 facilitates G1 checkpoint abrogation in HPV E7 expressing cells by modulating GCN5

BMC Cancer volume 20, Article number: 840 (2020) Cite this article

Abstract

Background

Genomic instability is a hallmark of cancer. The G1 checkpoint allows cells to repair damaged DNA that may lead to genomic instability. The high-risk human papillomavirus (HPV) E7 gene can abrogate the G1 checkpoint, yet the mechanism is still not fully understood. Our recent study showed that WDHD1 (WD repeat and high mobility group [HMG]-box DNA-binding protein 1) plays a role in regulating G1 checkpoint of E7 expressing cells. In this study, we explored the mechanism by which WDHD1 regulates G1 checkpoint in HPV E7 expressing cells.

Methods

NIKS and RPE1 derived cell lines were used. Real-time PCR, Rescue experiment, FACS and BrdU labeling experiments were performed to examine role of GCN5 in G1 checkpoint abrogation in HPV-16 E7 expressing cells.

Results

In this study, we observed that WDHD1 facilitates G1 checkpoint abrogation by modulating GCN5 in HPV E7 expressing cells. Notably, depletion of WDHD1 caused G1 arrest while overexpression of GCN5 rescued the inhibitory effects of WDHD1 knockdown on G1/S progression. Furthermore, siWDHD1 significantly decreased cell cycle proliferation and DNA synthesis that was correlated with Akt phosphorylation (p-Akt), which was reversed by GCN5 overexpression in HPV E7 expressing cells.

Conclusions

In summary, our data identified a WDHD1/GCN5/Akt pathway leading to the abrogation of G1 checkpoint in the presence of damaged DNA, which may cause genomic instability and eventually HPV induced tumorigenesis.

Peer Review reports

Background

The human papillomaviruses (HPVs) are spherical small DNA viruses that induce lesions in the skin and mucosa. The high-risk (HR) HPVs infection may lead to cervical cancer and other cancers. Up to 75% of cervical cancers are caused by HPV genotypes 16 and 18 [1]. The transforming properties of HR HPVs mainly depend on E6 and E7 oncogenes [2], which inactivate p53 and Rb family members respectively, thus abrogating cell cycle checkpoints [3]. HR HPV E7 can promote pRB degradation, which result in release of transcription factor E2F, transcription of genes required for DNA replication, and cell proliferation disorder [4,5,6,7,8].

The cell cycle progression is modulated at cell-cycle checkpoints by multiple factors such as cyclins, cyclin-dependent kinases (Cdks) [9]. Once the checkpoint becomes abnormal, genomic instability may occur [10]. Genomic instability is a hallmark of cancer progression [10], and G1 checkpoint determines whether cells can enter S phase for DNA replication. In the early G1 phase, pRb is partially phosphorylated of by Cdk4-Cdk6. pRb is completely phosphorylated by Cdk2 in the late G1 phase.

Genomic DNA of the normal cells duplicates only once per cell cycle. Replication starts in two steps: assembling and activating of pre-replication (pre-RC). The assembly of the pre-RC complex is regulated by cell cycle, which mainly occurs in the late mitosis and G1 phase. Prior to S phase, origins are licensed by the binding of components of the replicative DNA helicase in eukaryotes. Recognition complex (ORC), Cdc6, Cdt1 and MCM2–7 was recruited successively to the DNA replication starting point to participate in the assembly of the pre-RC complex and then initiate DNA replication [11]. It is generally believed that the DNA replication initiation factor affects the G1 checkpoint by regulating the initiation of DNA replication, which in turn causes G1 arrest. WDHD1 (WD repeat and HMG - box DNA - binding protein 1) was also shown to be involved in the assembly process [12]. In addition, WDHD1 act as a G1 checkpoint control protein [13,14,15]. How WDHD1 precisely regulates G1 checkpoint remains to be illucidated.

We have demonstrated a role for WDHD1 in G1 checkpoint control in HPV E7 expressing cells [16]. Our result suggests that WDHD1 may regulates G1 checkpoint through a mechanism independent of DNA replication initiation. This study aims to understand how WDHD1 regulates G1 checkpoint in E7 expression cells. It was reported that GCN5(histone acetyltransferase complex) plays a role in the G1 checkpoint control while WDHD1 inhibits degradation by disrupting its interaction with ubiquitination ligase CRL4 complex [17, 18]. Our recent study revealed that GCN5 promotes HPV expressing cell proliferation by regulating E2F1 [19]. In the present study, we determined the role of GCN5 and the mechanism by which WDHD1 abrogates G1 checkpoint in E7 expressing cells.

Methods

Cell culture

pBabe retroviral system was used to establish the HPV-16 E7 expressing NIKS and RPE1 cells as described previously [20]. Puromycin was used to maintain the above two cell lines, which are limited to be used within 15 generations [16].

RNA-seq

NIKS cells were used to extract total for construct cDNA libraries construction. The detailed operation processes please refer to the RNA-seq section of our published article [16].

Real-time PCR

According to the kit’s instructions, the entire RNA was separated with Qiagen RNeasy kit from the E7 expressing RPE1 or NIKS cells and their correspondent vector-control cells. Invitrogen cDNA synthesis kit and Bio-Rad SYBR Green Supermix were used for synthesis cDNA and Real-Time PCR. Details need to refer to the published articles [6, 16].

Flow cytometry

BrdU (bromodeoxyuridine) labeling and cell cycle experiments were performed on BD FACSAria™ III sorter equipment and analyzed by Cytomics™ FC500 Flow Cytometry CXP 2.0. The concentration of the Alexis Biochemicals bleomycin used in the experiment was 4 μg/ml. The specific experimental steps need to follow the published articles [16, 19, 20].

siRNAs and transfection

The Invitrogen Lipofectamine 2000 transfection reagent was used for gene knockdown and cell cycle analysis in E7 and vector-control expressing cells. The sequence of siRNA duplexes were in Table 1. Detailed experimental steps need to follow our published article [16].

Table 1 The sequence of siRNA duplexes
Full size table

Immunoblotting

Protein extracted from cells were measured by Pierce BCA (bicinchoninic acid), and then proceeded to SDS PAGE (polyacrylamide gel) electrophoresis, finally to be detected with antibodies against WDHD1 (abcam, ab72436), GCN5 (Santa Cruz, Sc-365,321), and tubulin (Sigma, T-4026), AKT (CST, 4685), p-AKT (CST, 4060). Detailed experimental steps need to follow our published article [16]. The Half Life Calculator was used to calculate the half-life of GCN5 which was treated with 25 μg/ml CHX (cycloheximide) (www.calculator.net).

Statistical analysis

Means and standard deviations (SDs) were used to present the data and the differences between means were compared by the student’s t-test. P < 0.05 was considered significant.

Results

Expression of GCN5 correlates with WDHD1 in HPV-16 E7 expressing cells

Our previous study demonstrated a role for WDHD1 in G1 checkpoint abrogation E7 expressing cells [16]. It was reported that GCN5 plays a role in the G1 checkpoint control while WDHD1 inhibits its degradation [17,18,19]. Moreover, our recent study revealed that GCN5 also promotes cell cycle progression in HPV E7 expressing cells [19]. We therefor hypothesize that WDHD1 performs its cell cycle promting function by up-regulating GCN5 in E7 expressing cells. We noticed that both WDHD1 and GCN5 expression were elevated in our RNA-seq data in HPV E7 expressing NIKs cells (Fig. 1a) [18]. This was confirmed by an RT-PCR analysis in both NIKS cells (Fig. 1b) and RPE1 cells (Fig. 1c).

Fig. 1
figure 1

GCN5 mRNA expression correlates with WDHD1. a GCN5 and WDHD1 mRNA levels in NIKs cells determined by RNA-seq. b and c GCN5 and WDHD1 mRNA levels in NIKS and RPE1 cells determined by real-time PCR. Error bars reflect the standard deviations of the mean. *, p < 0.05 **, p < 0.01

Full size image

Furthermore, the steady-state levels of WDHD1 and GCN5 were also increased in E7 expressing RPE1 cells (Fig. 2a). The increased steady-state level of GCN5 was regulated by WDHD1, as siRNA knockdown of WDHD1 reduced GCN5 while this reduction was reveres after transfection of cells with WDHD1 (Fig. 2b). We also determined the stability of GCN5 protein in E7 expressing cells. Accordingly, after treatment with cycloheximide, the steady-state levels of GCN5 in E7 expressing and vector control cells were measured (Fig. 2c). The results indicated that the half-life of GCN5 protein in E7 expression cells was significantly higher than that in the control cells (3.8 h versus 1.4 h).

Fig. 2
figure 2

GCN5 protein expression correlates with WDHD1. a GCN5 and WDHD1 protein levels in RPE1 cells. b GCN5 protein levels in RPE1 E7 cells examined by Western blotting after retransfected with Flag-WDHD1. Data were summarized (Right panel). c RPE1 cells were incubated with cycloheximide (CHX) and harvested at the indicated times. The stability of GCN5 was monitored by immunoblotting analyses (left panel). Data are summarized in the right panel. Data from a representative experiment of 3 are shown, *P < 0.05; **P < 0.01. The WB samples for quantitative comparisons on different gels/blots derive from the same experiment and that gels/blots were processed in parallel. Cropping is used for the gels and blots in the main paper and the ‘full-length blots/gels are presented in Supplementary Figure 2

Full size image

Overexpression of GCN5 overrides G1 checkpoint activation and S-phase entry delay induced by WDHD1 knock-down

We have demonstrated that both WDHD1 and GCN5 play key roles in S-phase entry and G1 checkpoint control in E7 expressing cells [16, 19], and our data suggest that WDHD1 regulates GCN5 expression (Figs. 1 and 2). To establish the functional interaction of the two molecules, we performed a rescue experiment. For this goal, we demonstrated that transfection of GCN5 can restore the steady-state levels of GCN5 protein caused by WDHD1 siRNA interference (Fig. 3a). Significantly, the percentage of cells arrested at the G1 phase as a result of WDHD1 knockdown was reduced after GCN5 expression (from 43.4 to 31.1%) (Fig. 3b). Similarly, percentage of BrdU incorporation due to WDHD1 knockdown was increased (from 24.3 to 31.6%) after GCN5 expression (Fig. 3c). These results demonstrated that the G1 abrogation and S-phase entry caused by WDHD1 knocking down could be rescued by up-regulating GCN5 in HPV E7 expressing cells.

Fig. 3
figure 3

Over expression of GCN5 rescues DNA replication reduction induced by WDHD1 depletion. a RPE1 cells expressing E7 were transfected with Flag-GCN5 or flag after WDHD1 siRNA transfection, and then cells treated with bleomycin for 36 h. Western blotting was used to determine the steady-state level of GCN5. Tubulin was used as a loading control. Right panel, quantification of relative GCN5 levels from 3 independent experiments. The WB samples for quantitative comparisons on different gels/blots derive from the same experiment and that gels/blots were processed in parallel. Cropping is used for the gels and blots in the main paper and the ‘full-length blots/gels are presented in Supplementary Figure 3A. b Cells were stained with PI after bleomycin treatment. G1, S and G2 phases are indicated and quantified. c Cells were stained with BrdU after bleomycin treatment, and analyzed by flow cytometry. Data from a representative experiment of 3 were shown. Error bars reflect the standard deviations of the mean. NC, negative control. *P < 0.05; **P < 0.01

Full size image

WDHD1 activates Akt via GCN5 in E7 expressing cells

It was reported that GCN5 regulates the G1 checkpoint by activating Akt [21]. As shown in Fig. 4a, activation of Akt, as indicated by its phosphorylation at 473, decreased after GCN5 knockdown, indicating that GCN5 regulates AKT activity in E7 expressing cells. We then examined whether WDHD1 could activate Akt by modulating GCN5, and found that GCN5 and p-Akt levels were greatly decreased in E7 expressing cells when WDHD1 were knocked down (Fig. 4b).

Fig. 4
figure 4

WDHD1 activates p-Akt expression to modulate cell cycle progression by up-regulating GCN5 in HPV E7 expressing cells. a The steady state levels of p-Akt by Western blot after GCN5 interference in RPE1 cells. b The steady state levels of p-Akt and GCN5 by Western blot after WDHD1 interference in RPE1 cells. c RPE1-E7 expressing cells were transfected with Flag-GCN5 or flag after WDHD1 siRNA transfection. The steady-state levels of p-Akt and GCN5 were measured by Western blotting. Tubulin was used as a loading control. Right panel, quantification of relative p-Akt levels from 3 independent experiments. Error bars reflect the standard deviations of the mean. NC, negative control. *P < 0.05; **P < 0.01. The WB samples for quantitative comparisons on different gels/blots derive from the same experiment and that gels/blots were processed in parallel. Cropping is used for the gels and blots in the main paper and the ‘full-length blots/gels are presented in Supplementary Figure 4

Full size image

We have already showed that expression of GCN5 can rescue G1 arrest caused by WDHD1 knockdown, we then asked whether expression of GCN5 can compensate for the inactivation of Akt caused by WDHD1 knockdown. As shown in Fig. 4c, expression of GCN5 can indeed compensate for Akt inactivation caused by WDHD1 knockdown. Therefore, taking all the results into consideration, cell cycle progression could be modulated by WDHD1 activating of Akt via GCN5 up-regulation in HPV E7 expressing cells.

Discussion

Licensing checkpoints including the DNA replication initiation factors regulate the S-phase entry [11, 21]. Previously, WDHD1 was thought to have a role in pre-RC assembly [13, 16]. However, the biochemical mechanism has not been verified at the cellular level in cervical cancer. Notably, we have demonstrated that even WDHD1 partially knocked down to control cells level can still induces G1 arrest [16], suggesting that besides the replication initiation mechanism, WDHD1 may regulate the G1 checkpoint through other mechanism or other target gene. In addition, WDHD1 is considered to be required for the stability of histone acetyltransferase GCN5 [18], the latter was reported to promote G1/S phase transition and cell cycle progression [22,23,24] by affecting its downstream target genes such as HBXIP [23], EGR2 [25], AIB1 [26], c-Myc [27, 28], E2F1 [22]. In addition to our recent results showing that GCN5 upregulates E2F1 and thus promotes HPV E7 induced cell proliferation [19], the other roles of GCN5 in cervical cancer are still unclear. This current study elucidates a model that HPV E7 up-regulates the expression of WDHD1 and then GCN5, which activates Akt and thereby promotes cell proliferation.

Due to the key regulatory role in multiple cell processes including cell proliferation, differentiation and apoptosis, AKT (also known as PKB) has received much attention in the field of life sciences. AKT signaling is typically activated in invasive squamous cell carcinomas [29, 30], including nearly 80% of cervical cancers [31,32,33]. However, the function of GCN5 activates AKT in cervical cancer has not been reported. Previous studies have shown that HPV E6 and E7 oncogenes augment the activation of AKT [32, 34]. Nonetheless, a recent study showed that HPV-16 E7 can attenuate pAKT signalling [35]. In addition, hypoxic AKT activation is observed under conditions of E6/E7 repression [36], which indicates that the hypoxic AKT activation is regulated by an E6/E7-independent mechanism, but the mechanism is unclear. These suggest that several pathways exist in activation of AKT signaling in HPV-positive cervical cancers. In this study, GCN5 was further discovered to modulate the cell cycle progression by activating p-Akt, and it’s over expression rescued the inhibition of G1/S transition due to WDHD1 reduction.

G1/S transition is regulated by cyclins, cyclin-dependent kinases (Cdks) and the regulatory proteins [9]. The G1 arrest observed in cells is associated with low levels of G1 Cdks activity and pRb hypophosphorylation. E6 and E7 oncoproteins abrogates cell cycle checkpoints and induces genomic instability by promoting the degradation of the tumour suppressors p53 and pRb, respectively. pRb binds to E2F and inhibits its transcriptional activation of genes, including cyclin A and cyclin E, which are important for the G1-S phase transition. p53 activates its target gene Cdk inhibitor p21 [37], which inactivates the cyclin E1/Cdk2 and cyclin A2/Cdk2 complexes, resulting in pRb hypophosphorylation and cell cycle arrest. Theoretically, p53 expression should be decreased due to E6 and has a low activity during carcinogenesis [38,39,40]. However, some studies have shown that p53 still functional in E7 expressing cells [41] and can be detected under hypoxia condition or after cytotoxic therapies that cause DNA damage in cervical tumors [42, 43]. These results suggest that p53 is still functioning in cervical cancer cells. Moreover, increased p21 expression was also observed in E7 expressing cells as well as cervical cancer [44, 45] and the expression of both p53 and p21 was increased in low-grade cervical squamous intraepithelial lesions infected with a wide variety of HPV types [46,47,48]. Furthermore, studies showed that oncogene E6 and E7 expression are different in lower grades of SIL (LSIL), with E7 expression predominating over E6 prior to the development of invasive cervical carcinoma [49]. The above-mentioned illustrated that p53 was still functional in E7 expressing cells as well as cervical cancer.

Polyploid, as one of the manifestations of genomic instability, has been recognized as an important cause of tumor genesis [50]]. The presence of polyploid cells could be examined in the early stages of cervical cancer [51],and our previous study showed that HPV-16 E7 can induce polyploid formation [52]. Generally known, one of the causes of polyploid formation is DNA re-replication, and there are few genes known to induce DNA re-replication currently. Our recent research results showed that the high-risk HPV-16 E7 can induce primary keratinized epithelial cells (PHK) to replicate in the G2 phase by increasing the DNA replication factor Cdt1, resulting in the formation of polyploid cells [20]. We also found that interference with WDHD1 significantly reduced the E7 induced DNA re-replication [16]. Then, whether WDHD1 can induce DNA replication by increasing GCN 5 remains to be further studied.

Conclusions

In summary, our data elucidate a model that HPV E7 up-regulates the expression of WDHD1 and then GCN5, which activates Akt and thereby promotes cell proliferation. These results will help understand the mechanism by which HPV regulates cell cycle and may contribute to develop drugs against the virus.

Availability of data and materials

The data sets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Abbreviations

WDHD1:

WD repeat and high mobility group [HMG]-box DNA-binding protein 1

GCN5:

General control nondepressible 5

HAT:

Histone acetyltransferase

HPV:

Human papillomaviruse

NIKS:

Spontaneously immortalized human foreskin keratinocytes

RPE1:

Retinal pigment epithelium cell line

BrdU:

Bromodeoxyuridine

FACS:

Fluorescence-activated cell sorting

CHX:

Cycloheximide

PI3K:

Phosphoinositide 3-kinase

References

  1. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):342–50.

    CAS  PubMed  Google Scholar 

  2. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006;110(5):525–41.

    CAS  Google Scholar 

  3. Fan X, Chen JJ. Regulation of cell cycle progression and apoptosis by the papillomavirus E6 oncogene. Crit Rev Eukaryot Gene Expr. 2004;14(3):183–202.

    CAS  PubMed  Google Scholar 

  4. Lee KA, Shim JH, Kho CW, Park SG, Park BC, Kim JW, Lim JS, Choe YK, Paik SG, Yoon DY. Protein profiling and identification of modulators regulated by the E7 oncogene in the C33A cell line by proteomics and genomics. Proteomics. 2004;4(3):839–48.

    CAS  PubMed  Google Scholar 

  5. Kuner R, Vogt M, Sultmann H, Buness A, Dymalla S, Bulkescher J, Fellmann M, Butz K, Poustka A, Hoppe-Seyler F. Identification of cellular targets for the human papillomavirus E6 and E7 oncogenes by RNA interference and transcriptome analyses. J Mol Med (Berl). 2007;85(11):1253–62.

    CAS  Google Scholar 

  6. Cortes-Malagon EM, Bonilla-Delgado J, Diaz-Chavez J, Hidalgo-Miranda A, Romero-Cordoba S, Uren A, Celik H, McCormick M, Munguia-Moreno JA, Ibarra-Sierra E, et al. Gene expression profile regulated by the HPV16 E7 oncoprotein and estradiol in cervical tissue. Virology. 2013;447(1–2):155–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Pang CL, Toh SY, He P, Teissier S, Ben Khalifa Y, Xue Y, Thierry F. A functional interaction of E7 with B-Myb-MuvB complex promotes acute cooperative transcriptional activation of both S- and M-phase genes. (129 c). Oncogene. 2014;33(31):4039–49.

    CAS  PubMed  Google Scholar 

  8. Chen JJ. Genomic instability induced by human papillomavirus oncogenes. N Am J Med Sci (Boston). 2010;3(2):43–7.

    Google Scholar 

  9. Murray AW. Recycling the cell cycle: cyclins revisited. Cell. 2004;116(2):221–34.

    CAS  PubMed  Google Scholar 

  10. Bochman ML, Schwacha A. The mcm complex: unwinding the mechanism of a replicative helicase. Microbiol Mol Biol Rev. 2009;73(4):652–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Shreeram S, Sparks A, Lane DP, Blow JJ. Cell type-specific responses of human cells to inhibition of replication licensing. Oncogene. 2002;21(43):6624–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Li Y, Xiao H, de Renty C, Jaramillo-Lambert A, Han Z, DePamphilis ML, Brown KJ, Zhu W. The involvement of acidic nucleoplasmic DNA-binding protein (And-1) in the regulation of prereplicative complex (pre-RC) assembly in human cells. J Biol Chem. 2012;287(51):42469–79.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Yoshizawa-Sugata N, Masai H. Roles of human AND-1 in chromosome transactions in S phase. J Biol Chem. 2009;284(31):20718–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Park SY, Im JS, Park SR, Kim SE, Wang HJ, Lee JK. Mimosine arrests the cell cycle prior to the onset of DNA replication by preventing the binding of human Ctf4/And-1 to chromatin via Hif-1alpha activation in HeLa cells. Cell Cycle. 2012;11(4):761–6.

    CAS  PubMed  Google Scholar 

  15. Zhu W, Ukomadu C, Jha S, Senga T, Dhar SK, Wohlschlegel JA, Nutt LK, Kornbluth S, Dutta A. Mcm10 and And-1/CTF4 recruit DNA polymerase alpha to chromatin for initiation of DNA replication. Genes Dev. 2007;21(18):2288–99.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhou Y, Zhang Q, Gao G, Zhang X, Liu Y, Yuan S, Wang X, Chen JJ. Role of WDHD1 in human papillomavirus-mediated Oncogenesis identified by transcriptional profiling of E7-expressing cells. J Virol. 2016;90(13):6071–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Li Y, Jaramillo-Lambert A, Hao J, Yang Y, Zhu W. The stability of histone acetyltransferase general control non-derepressible (Gcn) 5 is regulated by Cullin4-RING E3 ubiquitin ligase. J Biol Chem. 2011;286(48):41344–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Li Y, Jaramillo-Lambert AN, Yang Y, Williams R, Lee NH, Zhu W. And-1 is required for the stability of histone acetyltransferase Gcn5. Oncogene. 2012;31(5):643–52.

    PubMed  Google Scholar 

  19. Qiao L, Zhang Q, Zhang W, Chen JJ. The lysine acetyltransferase GCN5 contributes to human papillomavirus oncoprotein E7-induced cell proliferation via up-regulating E2F1. J Cell Mol Med. 2018;22(11):5333–45.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Fan X, Liu Y, Heilman SA, Chen JJ. Human papillomavirus E7 induces rereplication in response to DNA damage. J Virol. 2013;87(2):1200–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Ma Q, Fonseca A, Liu W, Fields AT, Pimsler ML, Spindola AF, Tarone AM, Crippen TL, Tomberlin JK, Wood TK. Proteus mirabilis interkingdom swarming signals attract blow flies. ISME J. 2012;6(7):1356–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Chen L, Wei T, Si X, Wang Q, Li Y, Leng Y, Deng A, Chen J, Wang G, Zhu S, et al. Lysine acetyltransferase GCN5 potentiates the growth of non-small cell lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression. J Biol Chem. 2013;288(20):14510–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Li L, Liu B, Zhang X, Ye L. The oncoprotein HBXIP promotes migration of breast cancer cells via GCN5-mediated microtubule acetylation. Biochem Biophys Res Commun. 2015;458(3):720–5.

    CAS  PubMed  Google Scholar 

  24. Koutsogiannouli EA, Wagner N, Hader C, Pinkerneil M, Hoffmann MJ, Schulz WA. Differential Effects of Histone Acetyltransferase GCN5 or PCAF Knockdown on Urothelial Carcinoma Cells. Int J Mol Sci. 2017;18(7):1449.

    PubMed Central  Google Scholar 

  25. Wang Y, Yun C, Gao B, Xu Y, Zhang Y, Wang Y, Kong Q, Zhao F, Wang CR, Dent SYR, et al. The lysine Acetyltransferase GCN5 is required for iNKT cell development through EGR2 acetylation. Cell Rep. 2017;20(3):600–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Majaz S, Tong Z, Peng K, Wang W, Ren W, Li M, Liu K, Mo P, Li W, Yu C. Histone acetyl transferase GCN5 promotes human hepatocellular carcinoma progression by enhancing AIB1 expression. Cell Biosci. 2016;6:47.

    PubMed  PubMed Central  Google Scholar 

  27. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene. 1999;18(19):3004–16.

    CAS  PubMed  Google Scholar 

  28. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151(1):56–67.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Kikuchi H, Kuribayashi F, Takami Y, Imajoh-Ohmi S, Nakayama T. GCN5 regulates the activation of PI3K/Akt survival pathway in B cells exposed to oxidative stress via controlling gene expressions of Syk and Btk. Biochem Biophys Res Commun. 2011;405(4):657–61.

    CAS  PubMed  Google Scholar 

  30. Shao G, Liu Y, Ma T, Zhang L, Yuan M, Zhao S. GCN5 inhibition prevents IL-6-induced prostate cancer metastases through PI3K/PTEN/Akt signaling by inactivating Egr-1. Biosci Rep. 2018;38(6):BSR20180816.

    PubMed  PubMed Central  Google Scholar 

  31. Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. Int J Cancer. 2006;118(8):1877–83.

    CAS  PubMed  Google Scholar 

  32. Menges CW, Baglia LA, Lapoint R, McCance DJ. Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. Cancer Res. 2006;66(11):5555–9.

    CAS  PubMed  Google Scholar 

  33. Stegeman H, Kaanders JH, Wheeler DL, van der Kogel AJ, Verheijen MM, Waaijer SJ, Iida M, Grenman R, Span PN, Bussink J. Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC Cancer. 2012;12:463.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Pim D, Massimi P, Dilworth SM, Banks L. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene. 2005;24(53):7830–8.

    CAS  PubMed  Google Scholar 

  35. Strickland SW, Vande Pol S. The human papillomavirus 16 E7 Oncoprotein attenuates AKT signaling to promote internal ribosome entry site-dependent translation and expression of c-MYC. J Virol. 2016;90(12):5611–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Bossler F, Kuhn BJ, Gunther T, Kraemer SJ, Khalkar P, Adrian S, Lohrey C, Holzer A, Shimobayashi M, Durst M, et al. Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling. mBio. 2019;10(1):e02323–18.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–10.

    CAS  PubMed  Google Scholar 

  38. Shaikh F, Sanehi P, Rawal R. Molecular screening of compounds to the predicted Protein-Protein Interaction site of Rb1-E7 with p53- E6 in HPV. Bioinformation. 2012;8(13):607–12.

    PubMed  PubMed Central  Google Scholar 

  39. Nair P, Somasundaram K, Krishna S. Activated Notch1 inhibits p53-induced apoptosis and sustains transformation by human papillomavirus type 16 E6 and E7 oncogenes through a PI3K-PKB/Akt-dependent pathway. J Virol. 2003;77(12):7106–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Massimi P, Banks L. Repression of p53 transcriptional activity by the HPV E7 proteins. Virology. 1997;227(1):255–9.

    CAS  PubMed  Google Scholar 

  41. Eichten A, Westfall M, Pietenpol JA, Munger K. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. Virology. 2002;295(1):74–85.

    CAS  PubMed  Google Scholar 

  42. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, Hill RP. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol. 2002;20(3):680–7.

    CAS  PubMed  Google Scholar 

  43. Haensgen G, Krause U, Becker A, Stadler P, Lautenschlaeger C, Wohlrab W, Rath FW, Molls M, Dunst J. Tumor hypoxia, p53, and prognosis in cervical cancers. Int J Radiat Oncol Biol Phys. 2001;50(4):865–72.

    CAS  PubMed  Google Scholar 

  44. Bae DS, Cho SB, Kim YJ, Whang JD, Song SY, Park CS, Kim DS, Lee JH. Aberrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus. Gynecol Oncol. 2001;81(3):341–7.

    CAS  PubMed  Google Scholar 

  45. Cheung TH, Lo KW, Yu MM, Yim SF, Poon CS, Chung TK, Wong YF. Aberrant expression of p21(WAF1/CIP1) and p27(KIP1) in cervical carcinoma. Cancer Lett. 2001;172(1):93–8.

    CAS  PubMed  Google Scholar 

  46. Giannoudis A, Herrington CS. Differential expression of p53 and p21 in low grade cervical squamous intraepithelial lesions infected with low, intermediate, and high risk human papillomaviruses. Cancer. 2000;89(6):1300–7.

    CAS  PubMed  Google Scholar 

  47. Cooper K, Herrington CS, Evans MF, Gatter KC, McGee JO. p53 antigen in cervical condylomata, intraepithelial neoplasia, and carcinoma: relationship to HPV infection and integration. J Pathol. 1993;171(1):27–34.

    CAS  PubMed  Google Scholar 

  48. Jeffers MD, Richmond J, Farquharson M, McNicol AM. p53 immunoreactivity in cervical intraepithelial neoplasia and non-neoplastic cervical squamous epithelium. J Clin Pathol. 1994;47(12):1073–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer. 2002;94(8):2199–210.

    CAS  PubMed  Google Scholar 

  50. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature. 2005;437(7061):1043–7.

    CAS  Google Scholar 

  51. Olaharski AJ, Sotelo R, Solorza-Luna G, Gonsebatt ME, Guzman P, Mohar A, Eastmond DA. Tetraploidy and chromosomal instability are early events during cervical carcinogenesis. Carcinogenesis. 2006;27(2):337–43.

    CAS  PubMed  Google Scholar 

  52. Banerjee NS, Wang HK, Broker TR, Chow LT. Human papillomavirus (HPV) E7 induces prolonged G2 following S phase reentry in differentiated human keratinocytes. J Biol Chem. 2011;286(17):15473–82.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors wish to thank the members of our laboratories for helpful discussions.

Funding

This work was supported by grants from the National Natural Science Foundation of China (81802761 and 81471944), Key Research and Development Program of Shandong Province (2019GSF107014) and China Postdoctoral Science Foundation (2019 M652405).

Author information

Authors and Affiliations

  1. Medical Research & Laboratory Diagnostic Center, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China

    Yunying Zhou, Fengyan Pei, Mingyu Ji, Fang Zhang, Yingshuo Sun, Qianqian Zhao, Xiao Wang, Yatian Hong, Juanjuan Tian & Yunshan Wang

  2. Department of Microbiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, 250012, Shandong, China

    Yunying Zhou, Yunshan Wang & Jason J. Chen

  3. Microbiology Department, Jinan Central Hospital Affiliated to Shandong first medical university, Jinan, China

    Yunying Zhou, Fengyan Pei, Mingyu Ji, Fang Zhang, Qianqian Zhao, Xiao Wang, Yatian Hong, Juanjuan Tian & Yunshan Wang

  4. Shandong LaiBo Biotechnology co., Ltd, Jinan, China

    Yunying Zhou

Authors
  1. Yunying Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fengyan Pei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mingyu Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yingshuo Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qianqian Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xiao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yatian Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Juanjuan Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yunshan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jason J. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JC concept and supervised the study. YW revised the manuscript. YZ was the major contributor in performing the research and drafting the manuscript. FP, MJ, YS, QZ, FZ, XW, YH and JT prepared all the figures. All authors have read and approved the manuscript.

Corresponding authors

Correspondence to Yunshan Wang or Jason J. Chen.

Ethics declarations

Ethics approval and consent to participate

None of the cell lines required ethics approval for their use.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, Y., Pei, F., Ji, M. et al. WDHD1 facilitates G1 checkpoint abrogation in HPV E7 expressing cells by modulating GCN5. BMC Cancer 20, 840 (2020). https://doi.org/10.1186/s12885-020-07287-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-020-07287-1

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us